These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

434 related items for PubMed ID: 15289888

  • 1. Imatinib mesylate (STI571) interference with growth of neuroectodermal tumour cell lines does not critically involve c-Kit inhibition.
    Te Kronnie G, Timeus F, Rinaldi A, Crescenzio N, Spinelli M, Rosolen A, Ricotti E, Basso G.
    Int J Mol Med; 2004 Sep; 14(3):373-82. PubMed ID: 15289888
    [Abstract] [Full Text] [Related]

  • 2. C-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions.
    Scotlandi K, Manara MC, Strammiello R, Landuzzi L, Benini S, Perdichizzi S, Serra M, Astolfi A, Nicoletti G, Lollini PL, Bertoni F, Nanni P, Picci P.
    J Clin Oncol; 2003 May 15; 21(10):1952-60. PubMed ID: 12743148
    [Abstract] [Full Text] [Related]

  • 3. Imatinib enhances human melanoma cell susceptibility to TRAIL-induced cell death: Relationship to Bcl-2 family and caspase activation.
    Hamaï A, Richon C, Meslin F, Faure F, Kauffmann A, Lecluse Y, Jalil A, Larue L, Avril MF, Chouaib S, Mehrpour M.
    Oncogene; 2006 Dec 07; 25(58):7618-34. PubMed ID: 16983347
    [Abstract] [Full Text] [Related]

  • 4. c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571).
    Hotfilder M, Lanvers C, Jürgens H, Boos J, Vormoor J.
    Cancer Chemother Pharmacol; 2002 Aug 07; 50(2):167-9. PubMed ID: 12172985
    [Abstract] [Full Text] [Related]

  • 5. Imatinib mesylate inhibits tumorigenicity of malignant fibrous histiocytoma cells in vivo.
    Irsan I, Akisue T, Hara H, Fujimoto T, Imabori M, Doita M, Kuroda R, Fujioka H, Kawamoto T, Yamamoto T, Kurosaka M.
    Anticancer Res; 2007 Aug 07; 27(1A):423-9. PubMed ID: 17352263
    [Abstract] [Full Text] [Related]

  • 6. Imatinib mesylate inhibits Leydig cell tumor growth: evidence for in vitro and in vivo activity.
    Basciani S, Brama M, Mariani S, De Luca G, Arizzi M, Vesci L, Pisano C, Dolci S, Spera G, Gnessi L.
    Cancer Res; 2005 Mar 01; 65(5):1897-903. PubMed ID: 15753388
    [Abstract] [Full Text] [Related]

  • 7. Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer.
    Wolff NC, Randle DE, Egorin MJ, Minna JD, Ilaria RL.
    Clin Cancer Res; 2004 May 15; 10(10):3528-34. PubMed ID: 15161712
    [Abstract] [Full Text] [Related]

  • 8. The c-kit tyrosine kinase inhibitor STI571 for colorectal cancer therapy.
    Attoub S, Rivat C, Rodrigues S, Van Bocxlaer S, Bedin M, Bruyneel E, Louvet C, Kornprobst M, André T, Mareel M, Mester J, Gespach C.
    Cancer Res; 2002 Sep 01; 62(17):4879-83. PubMed ID: 12208734
    [Abstract] [Full Text] [Related]

  • 9. Effects of imatinib vary with the types of KIT-mutation in gastrointestinal stromal tumor cell lines.
    Noma K, Naomoto Y, Gunduz M, Matsuoka J, Yamatsuji T, Shirakawa Y, Nobuhisa T, Okawa T, Takaoka M, Tomono Y, Hiroyuki O, Gunduz E, Tanaka N.
    Oncol Rep; 2005 Sep 01; 14(3):645-50. PubMed ID: 16077968
    [Abstract] [Full Text] [Related]

  • 10. Combined antiproliferative activity of imatinib mesylate (STI-571) with radiation or cisplatin in vitro.
    Yerushalmi R, Nordenberg J, Beery E, Uziel O, Lahav M, Luria D, Fenig E.
    Exp Oncol; 2007 Jun 01; 29(2):126-31. PubMed ID: 17704745
    [Abstract] [Full Text] [Related]

  • 11. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K, Jaboine J, Merchant MS, Mackall CL, Thiele CJ.
    J Natl Cancer Inst; 2004 Jan 07; 96(1):46-55. PubMed ID: 14709738
    [Abstract] [Full Text] [Related]

  • 12. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS, Woo CW, Mackall CL, Thiele CJ.
    J Natl Cancer Inst; 2002 Nov 20; 94(22):1673-9. PubMed ID: 12441322
    [Abstract] [Full Text] [Related]

  • 13. A general aspect on soft-tissue sarcoma and c-kit expression in primitive neuroectodermal tumor and Ewing's sarcoma. Is there any role in disease process?
    Kara IO, Gonlusen G, Sahin B, Ergin M, Erdogan S.
    Saudi Med J; 2005 Aug 20; 26(8):1190-6. PubMed ID: 16127511
    [Abstract] [Full Text] [Related]

  • 14. AKT mediates the pro-survival effects of KIT in ovarian cancer cells and is a determinant of sensitivity to imatinib mesylate.
    Shaw TJ, Vanderhyden BC.
    Gynecol Oncol; 2007 Apr 20; 105(1):122-31. PubMed ID: 17169414
    [Abstract] [Full Text] [Related]

  • 15. Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells.
    Sambol EB, Ambrosini G, Geha RC, Kennealey PT, Decarolis P, O'connor R, Wu YV, Motwani M, Chen JH, Schwartz GK, Singer S.
    Cancer Res; 2006 Jun 01; 66(11):5858-66. PubMed ID: 16740725
    [Abstract] [Full Text] [Related]

  • 16. Phase II clinical trial of imatinib mesylate in therapy of KIT and/or PDGFRalpha-expressing Ewing sarcoma family of tumors and desmoplastic small round cell tumors.
    Chao J, Budd GT, Chu P, Frankel P, Garcia D, Junqueira M, Loera S, Somlo G, Sato J, Chow WA.
    Anticancer Res; 2010 Feb 01; 30(2):547-52. PubMed ID: 20332468
    [Abstract] [Full Text] [Related]

  • 17. Effects of signal transduction inhibitor 571 in acute myelogenous leukemia cells.
    Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M.
    Clin Cancer Res; 2001 Dec 01; 7(12):3884-93. PubMed ID: 11751479
    [Abstract] [Full Text] [Related]

  • 18. [Effect of tyrosine kinase inhibitor Imatinib mesylate on proliferation, differentiation and apoptosis of Kasumi-1 leukemia cell line].
    Wang LH, Rao Q, Wang M, Wang JX.
    Zhonghua Xue Ye Xue Za Zhi; 2005 Aug 01; 26(8):449-52. PubMed ID: 16383232
    [Abstract] [Full Text] [Related]

  • 19. Induction of cell death by basic fibroblast growth factor in Ewing's sarcoma.
    Sturla LM, Westwood G, Selby PJ, Lewis IJ, Burchill SA.
    Cancer Res; 2000 Nov 01; 60(21):6160-70. PubMed ID: 11085540
    [Abstract] [Full Text] [Related]

  • 20. Stem cell factor is not essential for cell survival and proliferation of soft tissue sarcoma of neuroectodermal origin.
    Ricotti E, Bertorello N, Vai S, Pagani A, Cordero Di Montezemolo L, Madon E, Basso G.
    Haematologica; 1999 Oct 01; 84(10):879-86. PubMed ID: 10509034
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 22.